Company news
Eledon Pharmaceuticals, Inc. news in 2024
Eledon Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 11, 2024
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 28, 2024
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 28, 2024
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
September 3, 2024
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 13, 2024
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 28, 2024
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 8, 2024
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 6, 2024
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 6, 2024
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 27, 2024
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 24, 2024
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 20, 2024
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2024